AGT 103-T

N/A

Report date: 2023/05/19 15:50:44

Base Information

Drug NameAGT 103-T

Drug Alias NameAGT-103-transduced autologous T-cell therapyAGT 103-T

ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionReverse transcriptase modulatorsC-C chemokine receptor type 5 modulatorsC-X-C motif chemokine receptor 4 antagonists

TargetsC-C chemokine receptor type 5Reverse transcriptaseC-X-C motif chemokine receptor 4

Therapy Area/IndicationsHIV Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesAmerican Gene Technologies International Inc

China Registration ClassN/A

Develop Information

Active CompaniesAmerican Gene Technologies International Inc

Inactive CompaniesN/A

Active IndicationsHIV Infections

Inactive IndicationsN/A

Other Information

ATC CodeN/A